Contact Information: Inquiries Press Sidonie Myers +44 (0)1482 673246 Head of Communication Advanced Wound Management Investors and Analysts Liz Hewitt +44 (0)20 7401 7646 Group Director Corporate Affairs Smith & Nephew
Smith & Nephew Announces European Launch of ACTICOAT* Flex
| Source: Smith & Nephew PLC
HULL, ENGLAND--(Marketwire - September 2, 2009) - Smith & Nephew's (NYSE : SNN ) (LSE : SN )
Advanced Wound Management division, announce the European launch of
ACTICOAT™ Flex 3 and ACTICOAT™ Flex 7, to expand the ACTICOAT
portfolio. The Flex range provides enhanced conformability to better
address patient comfort and in utilizing the Silcryst™ nanocrystalline
silver technology, ACTICOAT Flex products have been designed to support
physicians dealing with soft tissue injuries at high risk of infection.
Both ACTICOAT Flex 3 and ACTICOAT Flex 7 were cleared for use by Health
Canada in late 2008. Dr. Sarvesh Logsetty, MD, FRCSC, FACS, Director of
Manitoba Firefighters Burn Unit and Associate Professor, Plastic & General
Surgery at the University of Manitoba commented on the product's excellent
performance characteristics. "ACTICOAT Flex is a natural addition to the
brand of dressings I trust when treating patients with wounds highly
susceptible to infection. These dressings are preferable when treating
wounds in areas of the body that require a high level of conformability and
when it is important to minimize trauma to the wound when removing the
dressing," stated Dr. Logsetty. "The Flex dressing allows exudate to pass
through, which is a great advantage," he explained.
"I am delighted that we can now offer our European clinicians this new
version of ACTICOAT. ACTICOAT Flex will provide a more flexible and
conformable option in dressing anatomical areas such as joints and helps
manage the risk of infection in patients with serious wounds," said Andy
Boyes, President Europe, Advanced Wound Management.
"The feedback on ACTICOAT Flex from the markets where it recently became
available has been excellent," commented Roger Teasdale, President of Smith
& Nephew Advanced Wound Management. "We are committed to improving the
quality of life of the patients treated with our products and ACTICOAT
Flex, often being used in combination with other brands in our portfolio,
is affecting that."
For more information regarding Smith & Nephew, please visit our Web site at
http://www.smith-nephew.com
* Trademark of Smith & Nephew
™ Trademark of Nucryst Pharmaceuticals
About Smith & Nephew
Smith & Nephew is a global medical technology business, specializing in
Orthopaedics, including Reconstruction, Trauma and Clinical Therapies,
Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader
in arthroscopy and advanced wound management and is one of the leading
global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company
prides itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous with
high standards of performance, innovation and trust. The Company operates
in 32 countries around the world. Annual sales in 2008 were nearly $3.8
billion.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the
meaning of the US Private Securities Litigation Reform Act of 1995. In
particular, statements regarding expected revenue growth and trading
margins discussed under "Outlook" are forward-looking statements as are
discussions of our product pipeline. These statements, as well as the
phrases "aim," "plan," "intend," "anticipate," "well-placed," "believe,"
"estimate," "expect," "target," "consider" and similar expressions, are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties
and other important factors (including, but not limited to, the outcome of
litigation, claims and regulatory approvals) that could cause the actual
results, performance or achievements of Smith & Nephew, or industry
results, to differ materially from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Please refer to the documents that Smith & Nephew has filed with the U.S.
Securities and Exchange Commission under the U.S. Securities Exchange Act
of 1934, as amended, including Smith & Nephew's most recent annual report
on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on
information available to Smith & Nephew as of the date hereof. All written
or oral forward-looking statements attributable to Smith & Nephew or any
person acting on behalf of Smith & Nephew are expressly qualified in their
entirety by the foregoing. Smith & Nephew does not undertake any
obligation to update or revise any forward-looking statement contained
herein to reflect any change in Smith & Nephew's expectation with regard
thereto or any change in events, conditions or circumstances on which any
such statement is based.